BioRestorative Therapies, Inc. is classed by the SEC under Services-Misc Health & Allied Services, NEC (industry code 8090), based in Melville, NY. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $360 thousand and a loss of $14 million (its filed statements).
Usage businessServices-Misc Health & Allied Services, NECMelville, NYfilings since 20108 of 9 filed, 1 estimated
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a usage business: prior from its industry code (SEC 8090, Services-Misc Health & Allied Services, NEC); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 3.4 out of ten, 8 of 9 metrics filed and 1 estimated: past 1.7 out of ten, present 3.0 out of ten, future 5.6 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 0.5 out of ten. 19 warning events since 2017; the latest 2026-09-10. 5th percentile among 11 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 2.6 out of ten. +20.5% a year over 9 filed years; profitable in 0 of 9. 26th percentile among 10 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 1.7 out of ten. CrossAssetData estimate 1.7/10, confidence 35 of 100 (one part). 17th percentile among 9 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
Financial health (present): 2.3 out of ten. ROE -3992%: lost 3992¢ per shareholder dollar. Leverage 91%: owes 91¢ per asset dollar. 23rd percentile among 10 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 3.5 out of ten. bottom 35% of 10 in its family; net margin -3959.4%. 35th percentile among 10 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 3.1 out of ten. bottom 31% of 7 in its family for leadership; chief executive since 2020. 31st percentile among 7 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
Room to expand (future): 7.1 out of ten. top 29% of 10 in its family for room to expand. 71st percentile among 10 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Growth drivers (future): 5.8 out of ten. top 42% of 10 in its family for growth drivers. 58th percentile among 10 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Expectations vs reality (future): 4.2 out of ten. bottom 42% of 10 in its family for expectations against reality. 42nd percentile among 10 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-03-26 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-05-14 for the period ended 2026-03-31 (on EDGAR). Newest results release: Form 8-K filed 2025-11-12 (on EDGAR). Newest filing: Form 8-K, 2026-10-09. Filings on record since 2010. Read from EDGAR 2026-10-12.
Where the revenue comes from
Product and service lines in fiscal 2025: Product 83%, Royalty 17%. As tagged in its annual report (Form 10-K, filed 2026-03-26).
Who runs it
Alstodt, Lance (President, CEO, COB); Silva, Francisco (VP of Research and Development); Randhawa, Esha (director); Brown, Steven Collier (director); Dhaliwal, Jatinder (director); Grasso, Mika (director); Field, Katharyn (director). 7 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.